Max Krakowiak: Hey, Dan. No, I think it will – similar to the Life Sciences instrument side, we are not expecting much of a volume step-up, if anything maybe in the applied genomics side, there might be a little bit of pressure quarter-over-quarter from a sequential volume standpoint. And so, I do think it will continue to be pressured here in the fourth quarter, maybe even so a little bit more than what we saw in the third quarter.
Daniel Arias: Okay. And then maybe, Prahlad, just big picture. I mean, is the state of the end-market environment right now impacting your view on M&A? Are you more or less enthused about doing another deal and does the priority list of the preference list, does it change at all just given the way that things are moving around here? Just curious about your appetite for additional M&A here?
Prahlad Singh: Yeah, it’s a great question. We continue to keep our M&A pipeline right, and we continue to look for opportunities. Obviously, we are going to be very diligent in terms of the valuation, et cetera. But strategically, the fundamentals of the business that we’ve established are focused on growth, which is differentiated. Obviously, the market has shifted in the short-term, but we are focused on ensuring that, A, we can control what we can right now and also we continue to build for the future. So we will continue to be active. I think the timing is something that is not predictable because, as you know, we are not really always looking for targets which are out in the public environment.
Daniel Arias: Okay. Helpful. Thank you.
Operator: Thank you. Our final question for today comes from Catherine Schulte of Baird. Your line is now open. Please go ahead.
Catherine Schulte: Hey, guys. Thanks for taking the questions. Maybe just on the comments on reexamining your midterm growth outlook. Is that more of a comment on the Life Sciences side of the business? Or do you think the Diagnostics side needs to be reevaluated as well?
Prahlad Singh: I think the way I would look at it, Catherine, is on the Diagnostics side, obviously, the applied genomics side of the business, where there is overlap with pharma/biotech. I would say that I would call out that, that’s probably a component that we would look at. But outside of that, the immunodiagnostics, the neonatal business that that is not something that we would see any impact on.
Catherine Schulte: Okay. And then I just want to clarify your comments on reagents for the fourth quarter. I think you both said that those would be flat versus the third quarter. Is that on a dollar basis sequentially? How should we think about reagents year-over-year growth rate in the fourth quarter?
Max Krakowiak: Yeah. Hey, Catherine. So for the reagent standpoint, the flat is actually the growth performance year-over-year. In terms of a dollar change versus the third quarter, it will be slightly up versus the third quarter.
Catherine Schulte: All right. Thank you.
Operator: Thank you. I will now hand back to Steve Willoughby for any further remarks.
Steve Willoughby: Thank you, Alex. I hope everyone has a good day, and we’re here all week. Take care.
Operator: Thank you for joining today’s call. You may now disconnect your lines.
